Evidence map›Paper›PMID 40991020›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Uridine-Based PET/NIRF Dual-Modality imaging for precision tumor diagnosis and surgery.

Linjie Bian, Panli Li, Yigang Chen, Simin He, Jianping Zhang, Xiaoping Xu, Jindian Li, Shaoli Song

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Linjie Bian *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Panli Li *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Yigang ChenDepartment of General Surgery, The Affiliated Wuxi Central Hospital of Jiangnan University, Wuxi, Jiangsu, 214100, China.
Simin HeDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Jianping ZhangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Xiaoping XuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Jindian LiDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. jindianli99@126.com.
Shaoli SongDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. shaoli-song@163.com.ORCID 0000-0003-2544-7522

Funding

National Isotope Engineering Technology Research Center Funding GJTWSGCZX-202306Shanghai Pujiang Program 22PJ1401700Shanghai Scientific and Technological Innovation Program 21XD1431300the construction project of Shanghai Key Laboratory of Molecular Imaging 18DZ2260400the State Key Program of the National Natural Science Foundation of China U23A20465
6 · The paper itself

Abstract

purposeMetabolic reprogramming allows cancer cells to survive and proliferate under nutrient-deprived conditions. Uridine, a central molecule in pyrimidine metabolism, supports both nucleotide biosynthesis and redox homeostasis. However, high-sensitivity imaging tools for equilibrative nucleoside transporter 1 (ENT1)-mediated uridine transport are lacking, limiting applications in precise diagnosis and intraoperative guidance. This study aimed to develop and validate a novel dual-modality imaging platform targeting ENT1-mediated uridine transport for tumor imaging and surgical navigation.

methodsWe synthesized [

results[

conclusionThis ENT1-targeted uridine transport PET/NIRF dual-modality imaging platform complements conventional glucose-based imaging and provides real-time intraoperative navigation. It holds significant promise for early cancer diagnosis and precision surgery with strong translational potential.

Indexed as

Optical ImagingPositron Emission Tomography Computed TomographyPrecision MedicineUridineAnimalsCell Line, TumorEquilibrative Nucleoside Transporter 1FemaleHumansMiceTissue DistributionEquilibrative Nucleoside Transporter 1UridineDual-modality imagingImage-guided surgeryMolecular imagingNIR-II fluorescenceUridine metabolism

Identifiers

PMID40991020

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.